Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indometacin is a potent non-steroidal anti-inflammatory drug (NSAID) belonging to the indole acetic acid derivative class. It functions as a non-selective inhibitor of the cyclooxygenase enzymes COX-1 and COX-2, which are responsible for the synthesis of prostaglandins from arachidonic acid. By reducing prostaglandin levels, indometacin effectively mitigates pain, fever, and inflammation. The specific product **Tuodu** (also marketed under the **Qingying** trademark) is a rectal suppository formulation manufactured by **Guangdong Xinxing Fenghua Pharmaceutical**. It is widely utilized in clinical practice for the management of inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis, as well as for the acute treatment of gouty arthritis and as an antipyretic for high fever.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indometacin.